TITLE: Preparation of 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)propanols and amino acid and peptide derivatives thereof as antihyperlipidemics.

INVENTOR(S): Kirsch, Reinhard; Enhsen, Alfons; Glombik, Heiner; Kramer, Werner; Falk, Eugen

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000020393	A1	20000413	WO 1999-EP6933	19990918
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19845406	A1	20000413	DE 1998-19845406	19981002
DE 19845406	C2	20011018		
CA 2345985	A1	20000413	CA 1999-2345985	19990918
AU 9961926	A	20000426	AU 1999-61926	19990918
AU 757689	B2	20030306		
BR 9915027	A	20010717	BR 1999-15027	19990918
EP 1117642	A1	20010725	EP 1999-948791	19990918
EP 1117642	B1	20040526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100896	T2	20010921	TR 2001-896	19990918
HU 2001003533	A2	20020228	HU 2001-3533	19990918
HU 2001003533	A3	20030128		
JP 2002526530	T	20020820	JP 2000-574510	19990918
RU 2224748	C2	20040227	RU 2001-111841	19990918
AT 267809	T	20040615	AT 1999-948791	19990918
PT 1117642	T	20040930	PT 1999-948791	19990918
ES 2219066	T3	20041116	ES 1999-948791	19990918
US 6596728	B1	20030722	US 1999-410083	19991001
ZA 2001002587	A	20011105	ZA 2001-2587	20010329
IN 2001CN00459	A	20050304	IN 2001-CN459	20010402
HK 1051533	A1	20050422	HK 2003-103726	20030527

PRIORITY APPLN. INFO.:

DE 1998-19845406	A	19981002
WO 1999-EP6933	W	19990918

OTHER SOURCE(S): MARPAT 132:279546

ED Entered STN: 14 Apr 2000

GI



I

AB Title compds. [I; R = Eq(A4)p(A3)o(A2)n(A1)mZ1; Z = NHACO, COACO, COQCO; A = alkylene; Q = phenylene; A1-A4 = (protected) amino acid residue; E = SO2R4, COR4; R1 = (substituted) Ph, thiazolyl, oxazolyl, thienyl, furyl, pyridyl, pyrimidinyl; R2 = H, OH, CH2OH, OMe; R3 = H, F, Me, OMe; R4 = alkyl, AR5, COAR5, etc.; R5 = CO2R6, COR6, (substituted) alkyl, Ph, naphthyl, thienyl, furyl, pyridyl, pyrimidinyl, chromanyl, thiazolyl, etc.; R6 = H, alkyl; l, m, n, o, p = 0, 1; l+m+n+o+p ≥1], were prepared Thus, I (R = H; R1 = Ph; R2, R3 = H) (preparation given) was treated with FMOC-D-Lys(BOC)-OH, TOTU, and Et3N in DMF followed by deprotection with piperidine in DMF to give 63.5% I [R = H-D-Lys(BOC); R1 = Ph; R2, R3 = H]. The latter was treated as above to give 43% I [R = H-D-Lys(BOC)-D-Lys(BOC); R1 = Ph; R2, R3 = H]. I inhibited [3H]-taurocholate uptake in rabbit ileum prepns. with quotients of IC50Na values of taurochenodesoxycholate and I of 0.16-1.26.

IT 263876-87-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)propanols and

amino acid and peptide derivs. thereof as antihyperlipidemics)

RN 263876-87-5 HCAPLUS

CN Acetamide, N-[2-[(1S,2R,3S)-3-hydroxy-3-phenyl-2-(2-pyridinyl)-1-(2-pyridinylamino)propyl]phenyl]-2-(2-pyrimidinylthio)- (CA INDEX NAME)

Absolute stereochemistry.



IC ICM C07D213-74

ICS C07D401-14; C07D409-14; C07D405-14; C07D417-14; C07D471-04; C07D473-04; C07D413-14; A61K031-4427

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 33
IT Amino acids, preparation
Peptides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)propanols and
amino acid and peptide derivs. thereof as antihyperlipidemics)
IT 263254-95-1P 263876-58-0P 263876-59-1P 263876-60-4P 263876-61-5P
263876-62-6P 263876-63-7P 263876-64-8P 263876-65-9P 263876-66-0P
263876-67-1P 263876-68-2P 263876-69-3P 263876-70-6P 263876-71-7P
263876-72-8P 263876-73-9P 263876-74-0P 263876-75-1P 263876-76-2P
263876-77-3P 263876-78-4P 263876-79-5P 263876-80-8P 263876-81-9P
263876-82-0P 263876-83-1P 263876-84-2P 263876-85-3P 263876-86-4P
263876-87-5P 263876-88-6P 263876-89-7P 263876-90-0P
263876-91-1P 263876-92-2P 263876-93-3P 263876-94-4P
263876-95-5P 263876-96-6P 263876-97-7P 263876-98-8P 263876-99-9P
263877-00-5P 263877-01-6P 263877-02-7P 263877-03-8P 263877-04-9P
263877-05-0P 263877-07-2P 263877-08-3P 263877-10-7P 263877-12-9P
263877-14-1P 263877-15-2P 263877-16-3P 263877-17-4P 263877-18-5P
263877-19-6P 263877-20-9P 263877-21-0P 263877-22-1P 263877-23-2P
263877-24-3P 263877-25-4P 263877-26-5P 263877-27-6P 263877-28-7P
263877-29-8P 263877-30-1P 263877-31-2P 263877-32-3P 263877-33-4P
263877-34-5P 263877-35-6P 263877-36-7P 263877-37-8P 263877-38-9P
263877-39-0P 263877-40-3P 263877-41-4P 263877-42-5P 263877-43-6P
263877-44-7P 263877-45-8P 263877-46-9P 263877-47-0P 263877-48-1P
263877-49-2P 263877-50-5P 263877-51-6P 263877-52-7P 263877-53-8P
263907-85-3P 263907-86-4P 263907-87-5P 263907-88-6P 263907-89-7P
263907-90-0P 263907-91-1P 263907-92-2P 263907-93-3P 263907-94-4P
263907-95-5P 263907-96-6P 263907-97-7P 263907-98-8P 263907-99-9P
263908-00-5P 263908-01-6P 263908-02-7P 263908-03-8P 263908-04-9P
263908-05-0P 263908-06-1P 263908-07-2P 263908-08-3P 263908-09-4P
263908-10-7P 263908-11-8P 263908-12-9P 263908-13-0P 263908-14-1P
263908-15-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)propanols and
amino acid and peptide derivs. thereof as antihyperlipidemics)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT